Circulation, Vol 74, 838-842, Copyright © 1986 by American Heart Association
D Collen, JM Stassen, DC Stump and M Verstraete
The existence of significant synergism between tissue-type plasminogen
activator (t-PA) and single-chain urokinase-type plasminogen activator
(scu-PA), and between t-PA and urokinase in thrombolysis in vivo is
described. In a quantitative preparation of thrombolysis, consisting of
rabbits in which a blood clot was induced in the jugular vein with 125I-
labeled fibrin, intravenous infusion over 4 hr of t-PA, scu-PA, or
urokinase in amounts of 0.5, 1.0, or 2.0 mg/kg body weight resulted in
significant thrombolysis (30% to 60%). The simultaneous infusion of t- PA
and scu-PA or of t-PA and urokinase had a significantly greater (p less
than .001) thrombolytic effect than could be anticipated on the basis of
the added effects of each agents alone. However, no synergism was observed
between scu-PA and urokinase. The observed alpha 2- antiplasmin consumption
and fibrinogen breakdown after urokinase at higher doses did not occur with
the equivalent thrombolytic combinations of t-PA and urokinase. The
combined use of synergic thrombolytic agents in patients may permit a
significant reduction in total administered doses, probably with
elimination of the systemic activation of the fibrinolytic system and the
concomitant fibrinogen breakdown that is unavoidable with the currently
used thrombolytic doses of each agent.
ARTICLES
Synergism of thrombolytic agents in vivo
This article has been cited by other articles:
![]() |
E. J. Harris JR and J. M. Porter Thrombolytic Therapy and Modern Vascular Surgery: An Overview Perspectives in Vascular Surgery and Endovascular Therapy, January 1, 1989; 2(2): 40 - 63. [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1986 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |